SCHEMBL10275600

SCHEMBL10275600

CC1=C(c2ccc(F)cc2F)CC2N(C)C(c3ccc(C#N)cc3)=CC(=O)N2N1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.34
PDE3B Q13370 2/20 0.33
PDE3A Q14432 2/20 0.33
MDM2 Q00987 1/20 0.33
AR P10275 1/20 0.32
WDR5 P61964 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GPR6 P46095 2/20 0.31
TACR1 P25103 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
KCNH2 Q12809 1/20 0.31
MAPK14 Q16539 1/20 0.30
DPP4 P27487 1/20 0.30
FNTA P49354 1/20 0.30
FNTB P49356 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275256 0.73 BRD4 (0.39) KDM1AKCNH2MAPK14DPP4FNTA
SCHEMBL10275941 0.72 MDM2 (0.34) KDM1APDE3BPDE3AMDM2AR
SCHEMBL10275845 0.70 AR (0.34) KDM1APDE3BPDE3AARGABRA1
SCHEMBL10276404 0.70 KDM1A (0.35) KDM1APDE3BPDE3AMDM2AR
SCHEMBL10275673 0.69 KDM1A (0.35) KDM1APDE3BPDE3AARWDR5
SCHEMBL10275487 0.68 AR (0.33) KDM1APDE3BPDE3AARGABRA1
SCHEMBL10275485 0.68 AR (0.33) KDM1APDE3BPDE3AARGABRA1
SCHEMBL10275863 0.68 PDE3B (0.34) KDM1APDE3BPDE3AARGABRG2
SCHEMBL10275221 0.66 MC4R (0.34) ARTACR1HTR2AHTR2CKCNH2
SCHEMBL10275638 0.65 KCNH2 (0.36) KDM1APDE3BPDE3AMDM2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 KDM1A 3996/4885PDE3B 2361/4885PDE3A 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.